Sirt6 Deficiency Worsens Kidney Damage in Hypertension by Altering Lipid Metabolism
Background
Chronic activation of the renin-angiotensin system by angiotensin II is a major driver of hypertension and progressive kidney disease, often leading to lipid nephrotoxicity in podocytes (specialized kidney cells essential for filtration). While Sirt6 (Sirtuin 6, a protein deacetylase) is known to play roles in metabolism and aging, its specific involvement in angiotensin II-induced lipid nephrotoxicity and its interaction with cardiolipin metabolism in podocytes remained unclear. This study aimed to elucidate how Sirt6 deficiency impacts PLD6-derived cardiolipin metabolism and exacerbates kidney damage under angiotensin II stress.
Results
The study revealed that Sirt6-deficient mice exhibited significantly worse kidney pathology compared to wild-type controls after angiotensin II infusion, showing a 2.8-fold increase in proteinuria and 43% more glomerular sclerosis. Specifically, Sirt6 deficiency led to a 3.5-fold increase in lipid droplet accumulation within podocytes and a 55% reduction in podocyte viability in vitro under angiotensin II stress (p<0.001). This exacerbation was linked to dysregulated cardiolipin metabolism: Sirt6 deficiency significantly increased PLD6 expression by 2.1-fold and reduced mature cardiolipin levels by 38% in podocytes, indicating a critical role for Sirt6 in maintaining mitochondrial lipid homeostasis. Furthermore, restoring Sirt6 expression in deficient podocytes reversed these effects, reducing lipid accumulation by 60% and normalizing PLD6 levels (p<0.01).
Why It Matters
This research provides crucial insights into the molecular mechanisms underlying angiotensin II-induced kidney damage, highlighting Sirt6 as a key regulator of lipid metabolism in podocytes. The findings suggest that targeting Sirt6 or its downstream pathways, particularly PLD6-derived cardiolipin metabolism, could offer novel therapeutic strategies for preventing or treating hypertensive nephropathy. Future research should focus on developing Sirt6 activators or modulators and testing their efficacy in larger animal models before progressing to human clinical trials (Phase I/II) for hypertensive kidney disease.